GlaxoSmithKline PLC (GSK): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

GlaxoSmithKline ( GSK) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.6%. By the end of trading, GlaxoSmithKline rose $1.01 (2.3%) to $45.57 on average volume. Throughout the day, three million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.5 million shares. The stock ranged in a price between $45.05-$45.66 after having opened the day at $45.10 as compared to the previous trading day's close of $44.56. Other companies within the Drugs industry that increased today were: Keryx Biopharmaceuticals ( KERX), up 38%, Cormedix ( CRMD), up 22.5%, Ventrus Biosciences ( VTUS), up 20.1%, and Theratechnologies ( THER), up 19.8%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $113.03 billion and is part of the health care sector. The company has a P/E ratio of 13.5, below the S&P 500 P/E ratio of 17.7. Shares are up 3% year to date as of the close of trading on Monday. Currently there are two analysts that rate GlaxoSmithKline a buy, one analyst rates it a sell, and eight rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the negative front, Anacor Pharmaceuticals ( ANAC), down 20.5%, Medgenics ( MDGN), down 7.7%, Telik ( TELK), down 7.5%, and Zogenix ( ZGNX), down 7%, were all laggards within the drugs industry with Arena Pharmaceuticals ( ARNA) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.